Rush University Medical Center, Department of Neurological Sciences, Chicago, Illinois, USA.
Stroke. 2012 Mar;43(3):875-7. doi: 10.1161/STROKEAHA.111.640060. Epub 2011 Dec 1.
We evaluated the impact that duration as a primary stroke center (PSC) had on tissue-type plasminogen activator (tPA) utilization for acute ischemic stroke.
A retrospective analysis of the Illinois Hospital Association CompData was performed identifying those patients with primary discharge diagnosis of acute ischemic stroke based on International Classification of Diseases version 9 codes. We assessed utilization of tPA by International Classification of Diseases version 9 procedure code (99.10). We categorized patients as cared for at non-PSC, PSC >1 year before, ≤1 year before, ≤1 year after, and >1 year after certification. We used generalized estimating equations to calculate adjusted odds ratios for tPA utilization by PSC category.
Among 119,539 acute ischemic stroke patients (mean age, 72 years; 55.2% women), tPA use was 1.9% but increased by PSC category (P<0.001): (1) non-PSC 0.9%; (2) >1 year before PSC certification 1.4%; (3) ≤1 year before certification 3.2%; (4) ≤1 year after certification 4.3%; and (5) >1 year after certification 6.5%. Adjusting for age, insurance status, admission source, year of study, region of Illinois, and hospital bed size, the odds of tPA utilization increased with advancing stage of PSC certification (highest category: adjusted odds ratio, 2.37; 95% confidence interval, 1.52-3.71).
Although increasing over time, stroke thrombolysis is strongly impacted by the PSC certification process. Rather than waning or stagnating, tPA utilization increases at PSC from the earliest phases of preparation through certification and subsequent maintenance.
我们评估了作为主要卒中中心(PSC)的时间长短对急性缺血性卒中患者使用组织型纤溶酶原激活剂(tPA)的影响。
我们对伊利诺伊州医院协会 CompData 进行了回顾性分析,根据国际疾病分类第 9 版(ICD-9)代码确定原发性出院诊断为急性缺血性卒中的患者。我们通过 ICD-9 操作代码(99.10)评估 tPA 的使用情况。我们将患者分为非 PSC、PSC 认证前 1 年以上、1 年以内、1 年以内、1 年以上。我们使用广义估计方程计算按 PSC 类别分类的 tPA 使用的调整后比值比。
在 119539 例急性缺血性卒中患者中(平均年龄 72 岁,55.2%为女性),tPA 的使用率为 1.9%,但随着 PSC 类别的增加而增加(P<0.001):(1)非 PSC 为 0.9%;(2)PSC 认证前 1 年以上为 1.4%;(3)认证前 1 年以内为 3.2%;(4)认证后 1 年内为 4.3%;(5)认证后 1 年以上为 6.5%。调整年龄、保险状况、入院来源、研究年份、伊利诺伊州地区和医院床位规模后,tPA 使用的可能性随着 PSC 认证阶段的推进而增加(最高类别:调整后的比值比为 2.37,95%置信区间为 1.52-3.71)。
尽管随着时间的推移而增加,但卒中溶栓治疗受到 PSC 认证过程的强烈影响。在 PSC 中,tPA 的使用从准备阶段到认证以及随后的维护阶段都在增加,而不是减弱或停滞。